[CAS NO. 170569-86-5] SC-236

Name: SC-236
Brand: Arctom Scientific
SKU: HY-W010983

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [170569-86-5]

Distributor

Catalog

HY-W010983

Brand

MCE

CAS

170569-86-5

DESCRIPTION [170569-86-5]

Overview

MDL	MFCD00941297
Molecular Weight	401.79
Molecular Formula	C16H11ClF3N3O2S
SMILES	O=S(C1=CC=C(N2N=C(C(F)(F)F)C=C2C3=CC=C(Cl)C=C3)C=C1)(N)=O

For research use only. We do not sell to patients.

Summary

SC-236 is an orally active COX-2 specific inhibitor ( IC ₅₀ = 10 nM) and a PPARγ agonist. SC-236 suppresses activator protein-1 ( AP-1 ) through c-Jun NH2-terminal kinase. SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model ^[1] ^[2] ^[3] ^[4] ^[5] .

IC50 & Target

COX-2

10 nM (IC ₅₀ )

COX-1

17.8 μM (IC ₅₀ )

In Vitro

SC-236 (15 μM, 30 min) suppresses the side effects of NSAIDs and prevented inflammation in vECs subjected to ALSS ^[1] .
SC-236 significantly induces PPARγ expression in HSCs and acted as a potent PPARγ agonist in a luciferase-reporter trans-activation assay ^[2] .
SC-236 strongly inhibits, in a time- and concentration-dependent manner, macrophage viability ^[2] .
SC-236, either alone or in combination with 15d-PGJ2, induced a marked pro-apoptotic effect in HSCs in culture ^[2] .
SC-236 mediates antitumor effect by modulation of AP-1-signaling pathway ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis ^[1]

Cell Line:	vECs.
Concentration:	15 μM
Incubation Time:	30 min.
Result:	Showd significant reduction in COX-2 level and increase in IκBα level, thus preventing ALSS-induced NFκB activation and inflammation in vECs.

Western Blot Analysis ^[2]

Cell Line:	COS 7 cells.
Concentration:	3 and 10 μM.
Incubation Time:	18 h (combined with 15d-PGJ ₂ ).
Result:	Acted in a concentration-dependent manner as a PPARγ agonist.

In Vivo

SC-236 (6 mg/kg, gavage) exhibits anti-fibrotic properties in CCl4- treated animals ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Seventy-six male adult Wistar rats weighing 200-220 g (CCl ₄ -treated) ^[2] .
Dosage:	6 mg/kg.
Administration:	Orally, 3 times per week.
Result:	A marked induction of COX-2 protein expression was detected by immunohistochemistry in the liver of CCl4-treated rats. Significantly reduced the degree of liver fibrosis. Dramatically suppressed α-SMA expression in CCl4-treated rats.

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 248.89 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4889 mL	12.4443 mL	24.8886 mL
5 mM	0.4978 mL	2.4889 mL	4.9777 mL
10 mM	0.2489 mL	1.2444 mL	2.4889 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Benzenesulfonamide, 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-

4-[5-(4-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide

SC 236

CID 9865808